ArticleInternational journal of molecular sciences2024
Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies.
Ana Vaz-Ferreira, Valéria Tavares, Inês Guerra de Melo, Patrícia Rafaela Rodrigues, Ana Afonso, Maria Joaquina Maurício, Rui Medeiros
Abstract read
In one paragraphArticle in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Ana Vaz-FerreiraOncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal.ORCID 0000-0002-7115-1880 Valéria TavaresMolecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/Pathology and Laboratory Medicine Department, Clinical Pathology SV/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto CCC), 4200-072 Porto, Portugal.ORCID 0000-0003-3680-7757 Inês Guerra de MeloMolecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/Pathology and Laboratory Medicine Department, Clinical Pathology SV/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto CCC), 4200-072 Porto, Portugal.
Patrícia Rafaela RodriguesOncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal.
Ana AfonsoOncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal.
Maria Joaquina MaurícioOncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal.
Rui MedeirosMolecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/Pathology and Laboratory Medicine Department, Clinical Pathology SV/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto CCC), 4200-072 Porto, Portugal.ORCID 0000-0003-3010-8373 Funding
Fundação para Ciência e Tecnologia (FCT) 2020.08969.BD; https://doi.org/10.54499/2020.08969.BDPortuguese Institute of Oncology of Porto (IPO Porto) CI-IPOP-22-2015
6 · The paper itselfAbstract
Prostate cancer (PC) is one of the most commonly diagnosed tumours among men. Second-generation androgen receptor axis-targeted (ARAT) agents, namely abiraterone acetate (AbA) and enzalutamide (ENZ), are currently used in the management of metastatic castration-resistant PC (mCRPC). However, the treatment is challenging due to the lack of prognostic biomarkers. Meanwhile, single-nucleotide polymorphisms (SNPs) have emerged as potential prognostic indicators of mCRPC. Thus, this study evaluated the impact of relevant SNPs on the treatment outcomes of 123 mCRPC patients enrolled in a hospital-based cohort study. The
Indexed as
Abiraterone AcetatePolymorphism, Single NucleotideProstatic Neoplasms, Castration-ResistantReceptors, AndrogenAdenocarcinomaAgedAged, 80 and overBenzamidesBiomarkers, TumorHumansMaleMiddle AgedNeoplasm MetastasisNitrilesPhenylthiohydantoinPrognosisAbiraterone AcetateBenzamidesBiomarkers, TumorCYP17A1 protein, humanenzalutamideNitrilesPhenylthiohydantoinReceptors, AndrogenSteroid 17-alpha-HydroxylaseY-Box-Binding Protein 1YBX1 protein, humanabiraterone acetatecastration resistanceenzalutamideprostatic neoplasmsSNPstreatment outcomes
Identifiers
PMID39337362
PMCPMC11432546
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390